Clinical Trial Update: Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of the combination inhaler QVA149A versus concurrent administration of QAB149 and NVA237 in chronic obstructive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237
• QAB149
• QVA149A

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-02-12